Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 9/20 | 0.36 |
| ▸ | CTSS | P25774 | 7/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28275184 | 0.82 | CYP2D6 (0.45) | CYP2D6TSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL21667012 | 0.82 | TSHR (0.32) | TSHR | |
| SCHEMBL1259909 | 0.81 | HDAC3 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL25907972 | 0.80 | CTSK (0.34) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4954427 | 0.79 | TSHR (0.48) | TSHRCA7 | |
| SCHEMBL6000874 | 0.78 | CA1 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11053349 | 0.77 | CYP2D6 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27322922 | 0.77 | TSHR (0.40) | TSHR | |
| SCHEMBL28632400 | 0.76 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28634513 | 0.76 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | CELGENE CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234914-A1 | PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE | CELGENE CORPORATION | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234914-A1 | PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE | UMPS, DHPS, NT5C3B | CYP2D6 272/4885TSHR 1670/4885HDAC3 2194/4885 |
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | UMPS, DHPS, NT5C3B | CYP2D6 272/4885TSHR 1670/4885HDAC3 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.